Neurocrine Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Neurocrine Biosciences generated cash of $389,900,000, which is more than the previous year. Cash used in financing activities reached the amount of $65,300,000 last year. Net change in cash is therefore -$11,600,000.
Cash Flow
| 2014 | -47.14M | -105.36M | 138.73M |
|---|---|---|---|
| 2015 | -37.99M | -195.81M | 276.99M |
| 2016 | -106.18M | 112.86M | 2.39M |
| 2017 | -94.33M | -250.87M | 516.64M |
| 2018 | 101.36M | -242.91M | 29.53M |
| 2019 | 152.05M | -211.07M | 27.31M |
| 2020 | 228.5M | 4.1M | -157.8M |
| 2021 | 256.5M | -130.2M | 27.4M |
| 2022 | 339.4M | -177.1M | -234.3M |
| 2023 | 389.9M | -467.1M | 65.3M |
NBIX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 270.7M | 344M | 190.3M | 115.5M | 147.19M | 259.21M | 83.26M | 74.19M | 31.01M | 44.78M |
Operating activities | ||||||||||
Net income | 249.7M | 154.5M | 89.6M | 407.3M | 37.01M | 21.11M | -142.54M | -141.09M | -88.92M | -60.54M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 21.3M | 15.6M | 10.9M | 8.6M | 7.45M | 4.02M | 2.4M | 1.45M | 1.00M | 827K |
Stock-based compensation expense | 194.3M | 173.1M | 134.2M | 100M | 75.26M | 0 | 42.52M | 28.46M | 28.39M | 10.38M |
| Deferred income tax benefit | 194.3M | 173.1M | 134.2M | 100M | 75.26M | 0 | 42.52M | 28.46M | 28.39M | 10.38M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -89.3M | -162.2M | -28.4M | -30.5M | -69.16M | -25.11M | -31.12M | 1.79M | -489K | -1.67M |
Inventories | 5.4M | -2.6M | -2.5M | -10.7M | -6.42M | -3.52M | -1.02M | -108K | -39K | 0 |
Accounts payable | 64.3M | 114.6M | 56.8M | 26.9M | 53.95M | 18.17M | 27.33M | 4.39M | 9.84M | 3.69M |
Cash generated by operating activities | 389.9M | 339.4M | 256.5M | 228.5M | 152.05M | 101.36M | -94.33M | -106.18M | -37.99M | -47.14M |
Investing activities | ||||||||||
Purchases Of Investments | -1.41B | -628.9M | -804.7M | -735.5M | -797.16M | -545.96M | -583.40M | -298.77M | -449.05M | -257.54M |
Investments In Property Plant And Equipment | -28.3M | -16.5M | -23.4M | -10.9M | -14.74M | -24.81M | -6.94M | -4.10M | -1.93M | -1.61M |
Acquisitions Net | 0 | -42.7M | 4.6M | 4 | 8K | 0 | 7K | 13K | 9K | 45K |
Cash generated by investing activities | -467.1M | -177.1M | -130.2M | 4.1M | -211.07M | -242.91M | -250.87M | 112.86M | -195.81M | -105.36M |
Financing activities | ||||||||||
Common Stock Issued | 65.3M | 44.7M | 27.5M | 29.1M | 27.31M | 29.53M | 13.86M | 2.39M | 276.99M | 138.73M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -279M | -100K | -186.9M | 0 | 0 | 502.78M | 0 | 0 | 0 |
Cash used in financing activities | 65.3M | -234.3M | 27.4M | -157.8M | 27.31M | 29.53M | 516.64M | 2.39M | 276.99M | 138.73M |
Net Change In Cash | -11.6M | -73.3M | 153.7M | 74.8M | -31.70M | -112.02M | 171.44M | 9.07M | 43.18M | -13.77M |
Cash at end of period | 259.1M | 270.7M | 344M | 190.3M | 115.48M | 147.19M | 254.71M | 83.26M | 74.19M | 31.01M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |